Summary: Fortunately > 80% of children diagnosed with cancer become long-term survivors; however, this population is at a significantly increased risk of morbidity and mortality as a result of their previous cancer therapy, and long-term follow-up (LTFU) is critical. Multiple barriers to receiving adequate LTFU care have been studied. We investigated whether lack of enrollment in a therapeutic clinical trial may be a barrier to receiving LTFU care. We conducted a review of 353 patient records at the Children's Hospital of Michigan enrolled in our Children's Oncology Group registry between January 1, 2005 and December 31, 2010. In total, 71 patients were excluded (death before follow-up, n = 61; currently receiving therapy, n = 5; known transfer of care, n = 4; insufficient information, n = 1). In total, 158 (56%) patients were enrolled in a therapeutic clinical trial. Follow-up rates at 1-, 2-and 5-years following completion of therapy for patients enrolled in a therapeutic clinical trial were 96.8% (153/158), 93.7% (148/158), and 81.7% (103/126), respectively, compared with 83.1% (103/124; P < 0.001), 74.2% (92/124; P < 0.001), and 66.7% (72/108; P = 0.001) for patients not enrolled. Our findings suggest patients enrolled in a therapeutic clinical trial have better LTFU rates and supports the importance of patient enrollment in therapeutic clinical trials when possible. Additional resources may be warranted to improve LTFU for patients not enrolled.
C hildhood cancer treatment outcomes have improved substantially over the past 40 to 50 years with 5-year overall survival rates reaching > 80% for children and adolescents, compared with rates of 50% to 60% in the 1970s. 1 As of 2011, nearly 400,000 survivors of childhood cancer were alive in the United States. 2 It is now well known that survivors are at significantly increased risk of long-term complications from their previous cancer treatment, and that long-term follow-up (LTFU) is critical. [3] [4] [5] [6] [7] The majority of survivors will develop adverse chronic health conditions within 30 years of their cancer diagnosis and are 10 times more likely than their siblings to develop a serious chronic disease. 4 The development of late effects is dependent on a multitude of factors, such as age at diagnosis, type of malignancy, treatment modalities utilized during therapy (ie, chemotherapy, radiation, surgery, hematopoietic stem cell transplant), and the presence of preexisting underlying comorbid conditions. 3, 8, 9 Despite the known increased morbidity and early mortality associated with childhood cancer survivorship, the majority of survivors may not be receiving adequate survivor-focused LTFU care. [10] [11] [12] In 2003, the Institute of Medicine recognized survivors of childhood and adolescent cancer as a vulnerable population in need of evidence-based guidelines for survivorship care. 3 As a result, the Children's Oncology Group (COG) established risk-based guidelines for survivors of childhood, adolescent and young adult (AYA) cancer to aid in improving the care of this population. 13, 14 Outcomes from utilizing these guidelines are being studied and have shown to be of high-yield for a number of screening modalities, such as assessing pulmonary and thyroid function in highrisk groups. 15 Unfortunately, multiple barriers and obstacles have been identified that may prevent survivors from receiving this necessary follow-up care. 16 One in particular is that many survivors of childhood and adolescent cancer are unaware that they are at risk of serious health problems as a result of their previous cancer diagnosis and treatment. 16, 17 Barriers range from those pertaining specifically to the survivor, such as this lack of knowledge, to other barriers involving health care providers and the health care system itself, such as lack of provider knowledge concerning survivors' care needs and a lack of insurance to afford follow-up care, respectively. 9, 16 Specific factors have been studied in an attempt to determine which patients may be at the greatest risk of not receiving adequate follow-up care. Risk factors that are associated with decreased LTFU rates include those such as lack of health insurance, male sex, lack of concern for future health, living at an increased distance from a cancer treatment center and increased time since completion of therapy. [10] [11] [12] [18] [19] [20] Nathan et al 11 reported that based on the results from the Childhood Cancer Survivor Study (CCSS), which has been previously described elsewhere, 21 only 13.7% of the 8522 survivors reported having received general survivor-focused care within the 2-year study period, and only 17.8% reported having received risk-based, survivor-focused care. Patients more likely to have received general or riskbased, survivor-focused care were those diagnosed with central nervous system tumors. Patients who were male, were uninsured or had a household income of <$40,000 per year were less likely to have received any type of medical care. 11 Additional factors may contribute to decreased followup rates that have not yet been identified. Although many young children diagnosed with cancer are enrolled in clinical trials, the AYA population historically enrolls at a much lower rate for a variety of reasons. 22 The aim of our study was to therefore determine whether lack of enrollment in a therapeutic clinical trial may be a barrier to receiving LTFU care among survivors of childhood and adolescent cancer.
MATERIALS AND METHODS
The Children's Hospital of Michigan is a tertiary care medical center located in Detroit, Michigan that delivers care to a racially and economically diverse patient population. After Institutional Review Board approval, a retrospective chart review of patients at the Children's Hospital of Michigan who were enrolled in our COG registry was conducted by a single investigator. Patients that are included in our COG registry consist of those who have consented to at least 1 clinical trial. These trials include-but are not limited to-biology and other nontherapeutic clinical trials, as well as therapeutic clinical trials (ie, prospective treatment trials). The patients who did not sign informed consent forms for various reasons (patient/family preference, family not offered, etc.) are included in a separate database. Patient records analyzed in the study include patients who were diagnosed with cancer at the Children's Hospital of Michigan between January 1, 2005 and December 31, 2010 and were 25 years of age or below at time of diagnosis. Descriptive data including sex, age at diagnosis, race (black, Middle Eastern, white, or other), ethnicity (Hispanic or nonHispanic), cancer diagnosis (brain tumor, leukemia, lymphoma, solid tumor, or other), economic status based on median income for zip code (low, middle, or high), insurance type (private or public), and enrollment in a therapeutic clinical trial (yes or no) were collected and analyzed. Electronic and paper medical records were utilized to collect data. Follow-up dates at 1-, 2-and 5-years postcompletion of therapy were manually recorded. Data analysis was conducted using SPSS version 24 (IBM Inc., Chicago, IL). Statistical significance was set at a P < 0.05 using a nonparametric 2-tailed Fisher exact test and the Pearson χ 2 test. Separate logistic regression analyses were then conducted among all collected patient variables for each of the 3 timepoints (1-, 2-, and 5-years postcompletion of therapy). Odds ratios (ORs) and their 95% confidence intervals (CIs) were obtained and reported for variables found to be significant predictors in the model, as well as for those that trended toward a P-value of 0.05.
RESULTS

Patient Characteristics
A total of 353 patients were enrolled in the registry and available for review. In total, 282 patient charts were included for analysis after 71 patients were excluded at 1-and 2-years postcompletion of therapy (died before followup, n = 61; still on therapy, n = 5; known transfer of care, n = 4; insufficient information, n = 1). In total, 234 patients were included for analysis at 5-years postcompletion of therapy (48 of the original 282 patients were still within 5 years of completing therapy). Demographic information for the patients included in the analysis is noted in Table 1 . In total, 158 (56%) patients were enrolled in a therapeutic clinical trial. In total, 185 (65.6%) patients were below 10 years of age at time of diagnosis. In total, 158 (56%) patients were male. The majority of patients were identified as white (152 patients, 53.9%), whereas 91 (32.3%) were identified as black. Almost all (269 patients, 95.4%) patients were identified as non-Hispanic. In total, 204 (72.3%) patients were categorized within the middle economic subgroup. The majority of diagnoses include solid tumors (106 patients, 37.6%) and leukemia (96 patients, 34%). Although 51.1% (144) of patients had private insurance, 48.2% (136) had public insurance. In total, 87% (245) of patients resided in the greater Detroit Tri-County area (Macomb, Oakland, and Wayne Counties).
Follow-up Outcomes
Patients enrolled in a therapeutic clinical trial had significantly better follow-up rates at 1-(96.8%, n = 153/ 158), 2-(93.7%, n = 148/158), and 5-years (81.7%, n = 103/ 126) postcompletion of therapy compared with those not enrolled in a therapeutic clinical trial (ie, those who consented to and were enrolled in a nontherapeutic clinical trial only) (83.1%, n = 103/124, P < 0.001; 74.2%, n = 92/124, P < 0.001; 66.7%, n = 72/108, P = 0.01, at 1-, 2-and 5-years, respectively) ( Table 2) . Significantly higher follow-up was also noted among patients with private versus public insurance at 2-and 5-years postcompletion of therapy (Table 2) . Patients diagnosed with malignancies other than solid tumors had significantly improved follow-up visit rates at 1-year postcompletion of therapy, as well as follow-up rates that trended toward significance at 2-and 5-years ( Table 2) . Patients who were younger than 10 years of age at time of diagnosis, as well as patients who were categorized within the higher economic status trended toward having improved follow-up rates at the various timepoints, although they were not statistically significant (Table 2 ). To discern if there was a difference specifically between children and the AYA population, patients were dichotomized into groups comparing those <15 and 15 years of age and above; however, there was a significantly unbalanced sample size, with ∼88% of patients being below 15 years of age at time of diagnosis. Patients' race and sex did not have an effect on LTFU rates ( Table 2 ). The single best predictor of follow-up at each of the 3 timepoints was enrollment in a therapeutic clinical trial when all variables were analyzed using a logistic regression model (1-year OR, 0.18, 95% CI, 0.06-0.49, P < 0.05; 2-years OR, 0.19, 95% CI, 0.09-0.41, P < 0.05; 5-years OR, 0.42, 95% CI, 0.23-0.79, P < 0.05).
The demographic data were then compared between the 2 groups of patients based on their therapeutic clinical trial enrollment status (Table 3) . Analyses were conducted between the group of 282 patients included at 1-and 2-years postcompletion of therapy based on enrollment status in a therapeutic clinical trial (Table 3A) , as well as between the 234 patients evaluable at 5-years postcompletion of therapy (Table 3B ). In the 1-and 2-year follow-up cohort, demographics were similar between the 2 groups with regard to age at diagnosis, sex, race, economic status, and type of insurance. There was an increased percentage of patients with types of malignancies other than solid tumors who were enrolled in a therapeutic clinical trial (39% of total cohort, 110 patients) compared with the percentage of patients with malignancies other than solids tumors who were not enrolled (23% of total cohort, 66 patients) (Table 3A) . Patient demographic data in the 5-year cohort were similar for all variables when comparing patients enrolled to those not enrolled in a therapeutic clinical trial (Table 3B ).
DISCUSSION
Survivors of childhood and AYA cancer are at increased risk of excess morbidity and early mortality. Unfortunately, many survivors are not receiving adequate risk-based, survivor-focused care. Multiple barriers have been shown to be associated with lack of LTFU. There was a significant increase in follow-up rates at 1-, 2-and 5-years postcompletion of therapy for patients enrolled in a therapeutic clinic trial compared with patients who were not among a cohort of survivors of childhood and AYA cancer at our institution. These data suggest that patients who are treated without being enrolled in a therapeutic clinical trial may not only be at risk of decreased survival rates and poorer quality of life as has been previously reported, 22 but may also receive inferior LTFU care which could then ultimately lead to increased morbidity and early mortality. Additional factors that were noted to be associated with increased rates of LTFU in this study included younger age at diagnosis, having private insurance, being diagnosed with a malignancy other than a solid tumor, and categorization in the high economic subgroup.
Patients who enrolled in nontherapeutic clinical trials alone at our institution may have been due to the lack of an open therapeutic clinical trial at the time of diagnosis. This finding was recently showed in a population-based study among Canadian children between 0 and 14 years of age diagnosed with cancer. 23 Pole et al 23 found that 27.5% *Patients enrolled in a therapeutic clinical trial had statistically greater follow-up at each of the 3 timepoints than patients not enrolled in a therapeutic clinical trial. Patients with private insurance had statistically greater follow-up at 2-and 5-years compared with patients with public insurance. The specific types of insurance were obtained from each medical record and then subcategorized as private or public. Patients with "other" forms of malignancy had greater follow-up rates at 1-year compared with patients with solid tumors. In the analyses, "solid tumor" includes retinoblastoma, soft tissue sarcomas, neuroblastoma, Wilms tumor, osteosarcoma, Ewing sarcoma, thyroid cancer, and germ cell tumor, whereas "other" includes patients with leukemia, brain tumors, lymphoma, Langerhans cell histiocytosis, transient myeloproliferative disorder, or hemophagocytic lymphohistiocytosis. Younger age at diagnosis trended toward improved follow-up rates. Race and sex did not significantly affect follow-up rates.
(2533/9204) of children in their Canadian database between 2001 and 2012 were enrolled in a therapeutic clinical trial. The primary reason documented as to why patients were not enrolled was due to lack of an open therapeutic clinical trial at time of diagnosis (52.2%) followed by physician choice (11.2%). Although the specific reasoning as to why each individual not enrolled in a therapeutic clinical trial at our institution is unknown, it is estimated that when open therapeutic clinical trials are available for a given patient's diagnosis > 90% of patients elect to enroll. This is important to recognize, particularly for adolescents and young adults diagnosed with cancer. It has been suggested that improved survival rates for childhood cancer over the years may in part be attributed to enrollment in clinical trials; however, improvements in the AYA population has not been as significant. 24, 25 One speculation as to why this is may be due to the lack of trial enrollment among the AYA population. 24, 26 The Division of Cancer Prevention and Control at the Centers for Disease Control and Prevention developed a working group of researchers and health care providers to study barriers to this population enrolling in clinical trials. 27 Barriers such as lack of an open available therapeutic clinical trial due to the type of cancer diagnosis, lack of knowledge from the providers' perspectives as to the importance of enrolling in a therapeutic trial, lack of collaboration between pediatric and adult oncology groups as well as between community and academic centers, and patient-specific barriers related to psychosocial issues and lack of insurance have been identified. 26, 27 The need for expanded access and accrual into therapeutic clinical trials has been recommended to increase not only scientific knowledge, but also treatment efficacy and to decrease treatment-associated morbidity. 24, 25 Many survivors may not be aware of the adverse sequelae that can result from their prior cancer history and treatment. 17, 28 Both survivors and their physicians have recognized the importance of survivors knowing details about their past diagnosis so that they are able to selfadvocate and participate in their own health care. 16, 29 Numerous collaborative and single-institution research efforts among survivors have been conducted to study the health issues faced by this population and support the need for ongoing, life-long follow-up, as well as further research to identify patients at greatest risk of adverse effects. 30, 31 It is recommended that to improve risk-based care for this vulnerable population interventions such as additional education for survivors and primary care physicians, as well as improved communication among survivors, their cancer centers and primary care physicians be developed. 10 This is of utmost importance as many primary care providers lack knowledge regarding the needs of survivors of childhood and adolescent cancer and feel uncomfortable taking care of this population. 8, 32 It is critical to be able to ensure adequate, quality follow-up for all patients, and determining specific barriers that put particular survivors at greatest risk of not seeking LTFU care is imperative so to focus on interventions that may help those most in need.
Our report is not without several limitations. First is the inherent nature of a retrospective review which may be associated with selection bias and confounding factors that were not accounted for in the analyses. Charts were obtained from the institution's COG registry but did not include patients who elected not to consent for a research study. Our data may therefore represent an overestimation of patients following-up at the given timepoints, as well as an overrepresentation of patients enrolled in a therapeutic clinical trial at our institution; however, including the patients not enrolled in any form of research study may have led to an even greater difference in LTFU rates between patients enrolled and not enrolled in a therapeutic clinical trial. A second limitation is that the data were collected from a single-institution by a single investigator. Given that this was an exploratory study, results still note an important association between LTFU rates and enrollment in therapeutic clinical trials and supports further investigation with a collaboration of institutions on this topic. Thirdly, followup data recorded in this study included any follow-up noted within our health care system and is not specific to riskbased, survivor-focused follow-up. In addition, there was a difference between the percentage of patients with malignancies other than solid tumors enrolled versus not enrolled in a therapeutic clinical trial at our institution for the 1-and 2-year cohort, which may confound the results and potentially skew the impact of inserting this variable into the model. Finally one cannot determine based on the data why patients who were not enrolled in a therapeutic clinical trial had decreased LTFU rates compared with those who were enrolled; however, one may speculate that a systems-based barrier may exist in that patients enrolled are closely followed to ensure adequate follow-up and reporting to the COG, which may provide increased assistance for those particular survivors.
In conclusion, our findings show that patients enrolled in a therapeutic clinical trial have significantly better LTFU rates compared with patients enrolled in nontherapeutic clinical trials alone. These data suggest that additional resources may be needed to improve LTFU for patients not enrolled in therapeutic clinical trials, as well as to ensure standardized institutional guidelines for monitoring the follow-up of all patients regardless of clinical trial enrollment status. These results support the importance of enrolling patients diagnosed with cancer in therapeutic clinical trials whenever possible. As the prevalence of survivors of childhood and adolescent cancer continues to increase, focus on improving health care follow-up rates should be a priority to provide necessary prevention and education for this vulnerable population. Further prospective research to determine possible reasons for lack of LTFU among survivors of childhood cancer including participation in clinical trials is warranted.
